ValuEngine upgraded shares of Tenax Therapeutics (NASDAQ:TENX) from a strong sell rating to a sell rating in a research note published on Friday.
Shares of Tenax Therapeutics (NASDAQ:TENX) opened at $0.32 on Friday. Tenax Therapeutics has a twelve month low of $0.30 and a twelve month high of $0.84. The firm has a market capitalization of $8.95, a PE ratio of -0.21 and a beta of 1.46.
A hedge fund recently bought a new stake in Tenax Therapeutics stock. Financial Advisory Service Inc. acquired a new position in Tenax Therapeutics Inc (NASDAQ:TENX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,291,932 shares of the specialty pharmaceutical company’s stock, valued at approximately $466,000. Financial Advisory Service Inc. owned about 4.58% of Tenax Therapeutics as of its most recent filing with the Securities and Exchange Commission. 10.27% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Tenax Therapeutics (TENX) Upgraded to Sell at ValuEngine” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thestockobserver.com/2018/02/06/tenax-therapeutics-tenx-upgraded-to-sell-at-valuengine.html.
About Tenax Therapeutics
Tenax Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.